Posted by James
A total of 119 patients were studied. Their mean age was 7.9±5.6 years. Sixty-eight (57.1%) of them were males and 51 (42.9%) were females, giving a male-female ratio of 1.3:1 As shown in Table 1, among 78 patients whose genotype were determined, 49 (62.8%) had hemoglobin genotype AA (HbAA) and 16 (20.5%) had HbSS, while seven (9%) and six (7.7%) had HbAS and HbAC, respectively. My Canadian Order net
Read the rest of this entry »
Posted by James
Treatment of HCV using pegylated interferon and tablet ribavirin has clearly improved upon SVR rates compared to the older formulations. However, differences in racial responsiveness to therapy continue to be reported. There have been several trials that have attempted to address the question of discordant response to treatment among different races. Historically, Reddy et al. first noted that African Americans had a significantly lower response to interferon monotherapy compared with other racial groups (SVR rates 2% versus 12%), but this study only had a small cohort of African Americans compared with Caucasians. McHutchison et al. initially studied this question utilizing standard interferon monotherapy versus combination therapy. Their study concluded that the seemingly impaired responsiveness of African Americans compared to Caucasians could be overcome with the advent of combination therapy, and they reported that SVR rates were similar for African Americans and non-African Americans with genotype l. However, subsequent studies did not match this equality in responsiveness.
Read the rest of this entry »
Posted by James
This study was carried out at the Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria. All pediatric and adolescent patients admitted between January 1996 and December 2002 were identified from the admission records of the orthopedic and pediatric services. These were compared with the central medical records to ensure completeness of identification. All patients with bone and soft tissue infections were then selected. Sociodemographic data as well as data of clinical presentation, genotype, bacterial isolates, and hematological profile were studied. Specimens for bacteriological studies were swabs/aspirates of pus from wounds, sinus, or ulcer. Anaerobic cultures were not done during the study period.
Read the rest of this entry »
Posted by James
Patient Demographics prior to Treatment
Table 1 outlines the baseline characteristics of our patient population, consisting of 73 individuals of multiethnic backgrounds who opted for therapy. This included 38 non-Hispanic Caucasians, 24 African Americans, three Hispanics, and eight Asian or Middle Easterners. There were a total of 50 patients who were genotype 1 and 23 patients who were nongenotype 1. The enrollment of the cohorts occurred concurrently, and the baseline characteristics of the groups were similar.
Read the rest of this entry »
Posted by James
Bacterial infections of bone and its soft tissue envelope are serious disease conditions especially in communities where abnormal hemoglobin genotype is common. The prevalence of HbSS and HbAS in Nigeria is 1.6-2% and 25-30%, respectively. Morbidity resulting from disabilities from some of these conditions may be life long. Mortality is also not infrequent. A review of death in the accident and emergency dept by Adesunkanmi et al. showed that pyomyositis accounted for 14% of deaths in surgical nontrauma conditions.
Read the rest of this entry »
Posted by James
INTRODUCTION
Bacterial MSS infections—including osteomyelitis, pyomyositis, and pyogenic arthritis, among others—are important causes of morbidity in children. Morbidity in these conditions may be increased by hemoglobinopathies.
Read the rest of this entry »
Posted by James
Patient Selection
Patients were recruited from an open-access, university-based hepatology clinic over a 24-month period between 2001 and 2003. Patients with chronic hepatitis С were selected for treatment if they were treatment-naive, had clinically well-compensated liver disease with detectable HCV RNA levels present at baseline and genotype determination. Most genotype-1 patients had a liver biopsy performed within the 12 months prior to initiating treatment. Patients were excluded from therapy if there was evidence of decompensated liver disease or other relative or absolute contraindications to treatment. Patients who had evidence of coinfection with hepatitis В or HIV (Generic Retrovir is used for treating HIV infection) were not included in this study. All prospective patients were appropriately counseled regarding treatment side effects with pegylated interferon and drug ribavirin, the need to avoid pregnancy and the requirement for at least monthly laboratory and clinical evaluations as well as the need to maintain compliance with treatment to optimize therapeutic response. All were ultimately given the freedom to decide on treatment or expectant management. If the patient opted to not receive treatment, the reason for this decision was recorded.